- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00475501
5-Alpha Reductase and Anabolic Effects of Testosterone
Study Overview
Status
Intervention / Treatment
Detailed Description
Approximately 40% of older male veterans have a low serum testosterone concentration. The latter is associated with diminished muscle strength and bone mineral density, depressed mood, low pain tolerance, frailty, and increased mortality. Replacement doses of testosterone have been administered to hypogonadal men for the purpose of reversing deficits in muscle and bone. Although testosterone is clearly important for maintaining muscle and bone in men, there are problems associated with T replacement. First, testosterone causes a number of undesired effects, including fluid retention, gynecomastia, worsening of sleep apnea, polycythemia, prostate enlargement and acceleration of early-stage prostate cancer. The anabolic effects obtained to date from testosterone replacement have been relatively modest, especially in older men. Our hypothesis is that combined treatment with a higher-than-replacement dose of testosterone and a 5- reductase inhibitor will produce substantial anabolic effects, while preventing testosterone-induced prostate enlargement and possibly other adverse effects.
We plan to investigate the efficacy and safety of combined treatment with testosterone and finasteride in older hypogonadal male veterans by conducting a 12-month randomized, placebo-controlled trial. We will administer a higher-than-replacement dose of testosterone plus the 5- reductase inhibitor finasteride to a group of hypogonadal, but otherwise healthy older men. We will determine whether this treatment is a safe and effective means to increase muscle mass and strength. Men aged 60 to 80, with circulating total testosterone 300 ng/dL or bioavailable testosterone 70 ng/dL, will be treated with 125 mg testosterone enanthate/week 5 mg finasteride/day for 1 year. We will assess the effects on body composition, 1- repetition maximum (1-RM) strength, grip strength, functional reach, bone mineral density, mood, cognition, hematopoiesis and prostate volume. We have chosen a moderately high dose of testosterone that may cause some adverse effects. We predict that finasteride will not block the anabolic effects of testosterone, but will block any prostate enlargement or symptoms and possibly other adverse effects as well.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32608
- North Florida/South Georgia Veterans Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 60 years males
- Primary care at the Malcolm Randall VA Medical Center in Gainesville, Florida.
- Consenting subjects who have a morning (between 6:00 AM and 10:00 AM) serum total testosterone 300 ng/dL or bioavailable testosterone concentration 70 ng/dL and no exclusion criteria will be randomized to receive either testosterone or placebo.
Exclusion Criteria:
- Subjects with cognitive impairment will be identified by the Mini-Cog test and excluded. The Mini-Cog has high sensitivity and specificity for cognitive impairment, and is not affected by level of education.
- We will also exclude subjects with receptive aphasia, or a contraindication to testosterone replacement (i.e., history of or active prostate or breast cancer, severe benign prostatic hyperplasia as assessed by elevated American Urologic Association Symptom Index (AUASI) score > 25), congestive heart failure (Class 3 or 4), sleep apnea syndrome, polycythemia (Hct > 55%), or prostate specific antigen (PSA) > 2.6 ng/mL) will be excluded.
- Obese subjects (BMI > 35) will also be excluded.
- Subjects currently receiving testosterone supplementation or subjects who have an allergy to testosterone will also be excluded.
- Subjects previously receiving testosterone replacement therapy must be off such medication for at least four weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
testosterone enanthate
|
125 mg, i.m. injection, once/week, for 52 weeks
Other Names:
|
Experimental: Arm 2
finasteride
|
5 mg, oral, once/day, for 52 weeks
Other Names:
|
Experimental: Arm 3
testosterone enanthate + finasteride
|
125 mg, i.m. injection, once/week, for 52 weeks
Other Names:
5 mg, oral, once/day, for 52 weeks
Other Names:
|
Placebo Comparator: Arm 4
placebo
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1 Repetition Maximum (1-RM) Strength Testing
Time Frame: baseline, 3 months, 6 months, 9 months, 12 months
|
1-RM strength testing for 5 exercises will be performed using dynamic resistance exercise machines.
Testing will be performed before treatment (baseline), at 3, 6, 9 and 12 months after treatment.
|
baseline, 3 months, 6 months, 9 months, 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Grip Strength kg
Time Frame: baseline, 3 months, 6 months, 9 months, 12 months
|
Grip strength in the dominant arm will be measured by using a dynamometer.
Testing will be performed at baseline, after 3, 6, 9 and 12 months of treatment.
|
baseline, 3 months, 6 months, 9 months, 12 months
|
Lumbar Spine L2-L4 Bone Mineral Density
Time Frame: baseline, 12 months
|
Dual x-ray absorptiometry (DXA): We will assess bone mineral density (BMD) and body composition using a fan-bean densitometer (Lunar Prodigy, General Electric Medical Systems).
|
baseline, 12 months
|
Geriatric Depression Scale
Time Frame: baseline, 3 months, 6 months, 9 months, 12 months
|
Geriatric Depression Scale (GDS): This 15-item, yes/no questionnaire will be administered at baseline, after 3, 6, 9 and 12 months of treatment. The minimum score is 0 = no depressive symptoms The maximum score is 15 = a very high level of depressive symptoms |
baseline, 3 months, 6 months, 9 months, 12 months
|
30 Minute Recall Portion of Rey Osterrieth Complex Figure (ROCF) Test
Time Frame: baseline, 3 months, 6 months, 9 months, 12 months
|
Rey Osterrieth Complex Figure (ROCF) test is a widely used standardized neuropsychological test for assessing visuospatial constructional functions, visuographic memory, and some aspects of planning. The drawing is scored by a blinded neuropsychologist on a scale of 0 to 30 with 30 representing a perfect drawing. |
baseline, 3 months, 6 months, 9 months, 12 months
|
Trail-Making Test, Part A
Time Frame: baseline, 3 months, 6 months, 9 months, 12 months
|
Trail-Making Test, Part A: is a standardized test of cognitive function which specifically assesses working memory, visual processing, visual spatial skills, selective and divided attention, and psychomotor coordination.
the test is scored as seconds required to successful completion of the task with a lower score representing better performance.
The mean score on test is 30.75 second with a standard deviation of 16.27.
|
baseline, 3 months, 6 months, 9 months, 12 months
|
Benton Judgment of Line Orientation Test
Time Frame: baseline, 3 months, 6 months, 9 months, 12 months
|
Benton Judgment of Line Orientation Test is a standardized test with 30 items that is specific for visual spatial cognition. Tests will be administered at baseline, after 3, 6, 9 and 12 months of treatment. The minimum score is 0, indicating low visual spatial cognition. The maximum score is 30, indicating high visual spatial cognition |
baseline, 3 months, 6 months, 9 months, 12 months
|
Hematocrit
Time Frame: baseline, 3 months, 6 months, 9 months, 12 months
|
Hematocrit was assessed as a part of routine blood analysis at the indicated time points.
|
baseline, 3 months, 6 months, 9 months, 12 months
|
Dietary Protein Intake
Time Frame: baseline, 3 months, 6 months, 9 months, 12 months
|
Dietary protein intake will be assessed using a 3-day food log and subjects will be counseled to increase protein intake if needed using the guide "Healthy Ways to Eat More Protein".
|
baseline, 3 months, 6 months, 9 months, 12 months
|
Transrectal Ultrasound Sizing of Prostate
Time Frame: baseline, 6 month, 12 months
|
Transrectal ultrasound sizing of prostate will be performed using the B&K Diagnostic System 3535, with 7 mega hertz transrectal probe at baseline and after 6 and 12 months of treatment.
|
baseline, 6 month, 12 months
|
Life Satisfaction
Time Frame: baseline, 3 months, 6 months, 9 months, 12 months
|
Life Satisfaction: is a written test of psychological well-being that will be performed at baseline, after 3, 6, 9 and 12 months of treatment.
This is a 20-point scale, with a possible range of scores from 0 to 20.
A higher score represents greater life satisfaction.
|
baseline, 3 months, 6 months, 9 months, 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stephen Borst, PhD, North Florida/South Georgia Veterans Health System
Publications and helpful links
General Publications
- Yarrow JF, Beck DT, Conover CF, Beggs LA, Goldberger BA, Borst SE. Invalidation of a commercially available human 5alpha-dihydrotestosterone immunoassay. Steroids. 2013 Dec 11;78(12-13):1220-5. doi: 10.1016/j.steroids.2013.08.013. Epub 2013 Sep 6.
- Borst SE, Yarrow JF, Conover CF, Nseyo U, Meuleman JR, Lipinska JA, Braith RW, Beck DT, Martin JS, Morrow M, Roessner S, Beggs LA, McCoy SC, Cannady DF 2nd, Shuster JJ. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E433-42. doi: 10.1152/ajpendo.00592.2013. Epub 2013 Dec 10.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Endocrine System Diseases
- Gonadal Disorders
- Prostatic Diseases
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Atrophy
- Prostatic Hyperplasia
- Sarcopenia
- Muscular Atrophy
- Hypertrophy
- Hypogonadism
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Urological Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Androgens
- 5-alpha Reductase Inhibitors
- Anabolic Agents
- Testosterone
- Methyltestosterone
- Testosterone undecanoate
- Testosterone enanthate
- Testosterone 17 beta-cypionate
- Finasteride
Other Study ID Numbers
- ENDA-014-05F
- VA Merit Award (Other Grant/Funding Number: VHA AR6884R)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcopenia
-
University of Texas at AustinNot yet recruitingExercise Training and SarcopeniaUnited States
-
Centre Hospitalier Universitaire DijonCompleted
-
Creighton UniversityUniversity of NebraskaRecruiting
-
University Hospital, CaenCompleted
-
University of NottinghamUniversity of OxfordRecruitingMuscle Atrophy | Age-Related SarcopeniaUnited Kingdom
-
Tufts UniversityNational Institute on Aging (NIA)CompletedMuscle Loss | Age-Related SarcopeniaUnited States
-
China Medical University HospitalCompleted
-
King's College LondonCo-sponsor: Guy's and St Thomas' NHS Foundation TrustCompletedFrailty | Sarcopenia | Age-Related SarcopeniaUnited Kingdom
-
Norwegian School of Sport SciencesOslo University HospitalNot yet recruitingHealthy Aging | Testosterone Deficiency | Age-Related Sarcopenia
-
Ningbo Medical Center Lihuili HospitalCompletedHemodialysis Patients With SarcopeniaChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States